Sanofi 'Selecta's Early Stage Immunotherapy in $900M Deal
Nanomedicine specialist Selecta Biosciences Inc., which has moved with rapid-fire speed over the past two years, landed a potential $900 million deal with Sanofi SA to discover targeted, antigen-specific immunotherapies for food allergies.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter